Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label Aurion Study in Lupus Nephritis

Source: Aurinia Press Release

Aurinia Pharmaceuticals Inc. announced that it has completed an analysis of the first seven patients to complete 24 weeks in its open-label AURION (Aurinia early Urinary protein Reduction Predicts Response) study. At 24 weeks 57% (4/7) of patients continued to be in complete remission. Remission was defined by a test measuring proteinuria -- excessive protein in the urine -- along with the need for steroids at a dosage of less than 5mg/day. Among these seven AURION patients there was an average reduction of 54%  in proteinuria at 24 weeks compared to pre-treatment levels along with consistent improvements in other indicators. Kidney function remained stable and no new safety signals were observed.